A differentiated CAR T-cell therapy shows strong safety and efficacy in real-world and clinical settings, with expanding adoption and revenue growth. Ongoing studies target broader oncology and autoimmune indications, with key data readouts expected through 2028.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.